This study presents the major business opportunities emerging in the global cancer diagnostics market during the next five years. The report examines trends in the U.S., Europe and Asia; reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by country and market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers.
Rationale
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.
Geographic Coverage
France, Germany, Italy, Japan, Spain, UK, USA
Worldwide Market Overview
Strategic assessments of major suppliers and start-up firms developing innovative cancer diagnostic technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.
The companies analyzed in the report include:
Rationale
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.
Geographic Coverage
France, Germany, Italy, Japan, Spain, UK, USA
Worldwide Market Overview
- Five-year test volume and sales projections by country.
- Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers by country.
- Estimated universe of laboratories performing cancer diagnostic testing by country.
- Cancer statistics, etiology and recent developments in the U.S., Europe, and Asia.
- Specific new product development opportunities with potentially significant market appeal during the next five years.
- Design criteria for new products.
- Alternative market penetration strategies.
- Potential market entry barriers and risks.
- Oncogenes
- Biochemical Markers
- Growth Factors
- Colony Stimulating Factors
- Hormones
- Immunohistochemical Stains
- Lymphokines
- Sales and market shares of major cancer diagnostic product suppliers by individual test and country.
- Five-year test volume and sales forecasts for major tumor markers by country and market segment, including:
- Hospitals
- Commercial/Private Laboratories
- Physician Offices/Group Practices
- Cancer Clinics
- Ambulatory Care Centers
- Analysis of major molecular diagnostic and immunodiagnostic analyzers used for cancer testing, including their operating characteristics, features and selling prices.
- Assessment of latest technologies and their potential applications for cancer diagnostic testing.
- Review of competing/complementing technologies.
- Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies.
Strategic assessments of major suppliers and start-up firms developing innovative cancer diagnostic technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.
The companies analyzed in the report include:
- Abbott
- Agilent Technologies
- Arca Biopharma
- Beckman Coulter/Cepheid/Danaher
- Becton Dickinson bioMerieux
- Bio-Rad
- CellSearch
- Clinical Genomics
- Decode Genetics
- DiaSorin
- Diazyme
- Eiken Chemical
- Elitech Group
- Enzo Biochem
- Epigenomics
- Erba Mannheim
- Exact Sciences
- Fujifilm Wako
- Fujirebio
- Grifols
- GSK
- Guided Therapeutics
- Hologic
- Janssen Diagnostics
- Leica Biosystems
- Lonza
- Kyowa Medex
- LabCorp
- Myriad Genetics
- OncoLab
- PerkinElmer
- Polymedco
- Qiagen
- Quest Diagnostics
- QuidelOrtho
- Roche
- Scienion
- Siemens Healthineers
- Takara Bio
- Theradiag
- Thermo Fisher
- Tosoh
